Integra LifeSciences Net Income From Continuing Ops Over Time
| IART Stock | USD 11.09 0.21 1.93% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Integra LifeSciences Performance and Integra LifeSciences Correlation. Is there potential for Health Care Equipment & Supplies market expansion? Will Integra introduce new products? Factors like these will boost the valuation of Integra LifeSciences. Market participants price Integra higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Integra LifeSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.004 | Earnings Share (6.47) | Revenue Per Share | Quarterly Revenue Growth 0.056 | Return On Assets |
Understanding Integra LifeSciences requires distinguishing between market price and book value, where the latter reflects Integra's accounting equity. The concept of intrinsic value—what Integra LifeSciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Integra LifeSciences' price substantially above or below its fundamental value.
Please note, there is a significant difference between Integra LifeSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Integra LifeSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Integra LifeSciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income From Continuing Ops Analysis
Compare Integra LifeSciences and related stocks such as Tandem Diabetes Care, Pacific Biosciences, and Maravai Lifesciences Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TNDM | (79.5 M) | (79.5 M) | (79.5 M) | (79.5 M) | (79.5 M) | (72.4 M) | (83.4 M) | (73 M) | (122.6 M) | (24.8 M) | (34.4 M) | 15.6 M | (94.6 M) | (222.6 M) | (96 M) | (86.4 M) | (90.7 M) |
| PACB | (109.4 M) | (109.4 M) | (94.5 M) | (79.3 M) | (66.2 M) | (31.7 M) | (74.4 M) | (92.2 M) | (102.6 M) | (102.1 M) | (102.6 M) | (181.2 M) | (314.2 M) | (309.1 M) | (309.9 M) | (278.9 M) | (264.9 M) |
| MRVI | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (16.9 M) | (5.2 M) | 78.8 M | 469.2 M | 490.7 M | 59 M | (259.6 M) | (233.7 M) | (222 M) |
| SEPN | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | 4.2 M | (71.8 M) | (64.6 M) | (61.4 M) |
| FTRE | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | (359.2 M) | 98 M | 58.4 M | (3.4 M) | (271.5 M) | (312.2 M) | (296.6 M) |
| MYGN | 112.2 M | 112.2 M | 112.2 M | 147.1 M | 176.2 M | (199.6 M) | (199.6 M) | (199.6 M) | (199.6 M) | (199.6 M) | (27.2 M) | (27.2 M) | (112 M) | (263.3 M) | (127.3 M) | (114.6 M) | (108.8 M) |
| BCAX | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (52 M) | (68 M) | (61.2 M) | (64.3 M) |
| EYPT | (24.8 M) | (24.8 M) | (11.9 M) | (13.4 M) | 6.3 M | (21.5 M) | (18.5 M) | (53.2 M) | (86.1 M) | (56.8 M) | (45.4 M) | (58.4 M) | (102.3 M) | (70.8 M) | (130.9 M) | (117.8 M) | (111.9 M) |
| INMD | 336 K | 336 K | 336 K | 336 K | 336 K | 336 K | 336 K | 8.8 M | 22.4 M | 61.2 M | 75 M | 165.1 M | 161.5 M | 197.9 M | 181.3 M | 208.5 M | 106.8 M |
| BFLY | (99.7 M) | (99.7 M) | (99.7 M) | (99.7 M) | (99.7 M) | (99.7 M) | (99.7 M) | (99.7 M) | (99.7 M) | (99.7 M) | (162.7 M) | (32.4 M) | (168.7 M) | (133.7 M) | (72.5 M) | (83.4 M) | (87.5 M) |
Integra LifeSciences and related stocks such as Tandem Diabetes Care, Pacific Biosciences, and Maravai Lifesciences Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Integra LifeSciences Holdings | IART |
| Classification | Obamacare Repeal |
| Business Address | 1100 Campus Road, |
| Exchange | NASDAQ Exchange |
USD 11.09
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.